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Methods for Assessing Mortality in
Parkinson’s Disease Surveys
Posada et al.1 recently published a report on mortality in
Parkinson’s disease (PD) patients in a prospective substudy of
neurological disorders in Central Spain, the neurological dis-
orders in Central Spain (NEDICES) study. The report used a
population-based data-collection method to avoid referral
selection biases, and the investigators concluded that PD was
an independent predictor of mortality in the elderly.1 Based
on the literature, there is a wide range of reported data for
mortality rates and hazard ratios (HRs) in PD from different
sampling methods and statistical procedures.
Standardized mortality rate (SMR) is among the most fre-
quently used indices used for PD surveys.2 It is important to
calculate an age-adjusted SMR that excludes the effect of
different age distributions between PD patients and healthy
individuals. Another life-table–related index is the PD-spe-
cific life expectancy (LE). LE calculations make it possible to
compare the mortality effects of PD between patients and
controls with different mean ages. This is a subject of con-
tention in many surveys, such as Posada et al.’s,1 where PD
subjects were significantly older than the general population
(77.0 versus 74.3 years). In line with Posada et al.,1 other
investigators have focused on survival and HR. In such
cases, Cox’s proportional hazards analyses are normally
used to adjust the risk of PD mortality with regard to base-
line confounding variables. Although after adjustment HRs
of mortality remained elevated in PD patients, it was consid-
erably reduced from 2.29 [95% confidence interval [CI]:
1.80–2.93] to 1.75 (95% CI: 1.32–2.31).1 Nevertheless, it
should be noted that such a multivariate adjustment with
consideration of numerous confounders and covariates in a
sample size of 81 PD patients with 66 deaths may reduce
statistical power. The onset age of PD should be taken into
account in evaluations of mortality in PD. Previous surveys
have shown that LE and survival reduction is significantly
more pronounced in PD patients with early onset of the dis-
ease.3,4 Posada et al.1 only recruited cases 65 years of age
and above, and many young-onset PD patients were
excluded at the time of enrollment. Thus, an unadjusted HR
signified a higher mortality rate in PD patients with old
onset (i.e., 65 years; 2.36 [95% CI: 1.79–3.12] versus 2.08
[95% CI: 1.25–3.45]), and after multiple adjustment, the
rate was superseded by that of the earlier onset cases (i.e.,
<65 years; 1.73 [95% CI: 1.28–2.36] versus 1.81 [95% CI:
0.96–3.38]).1 It seems that the adjusted HR for early-onset
PD patients failed to reach the statistically significant level,
because the 95% CI of the estimation includes the value of
1.0. Despite evaluation of the effect of early onset of the dis-
ease on mortality, the study underestimated the role of
young-onset patients in PD mortality by the inclusion of
only those individuals 65 years and older. In other words,
the NEDICES survey only assessed the young-onset PD cases
that lived to more than 65 years.
In conclusion, it can be recommended that different meth-
ods of mortality assessment should be taken into considera-
tion, and that recruitment should be extended to include
cases with early onset of PD as well.
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